Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 116


High content image-based screening of a protease inhibitor library reveals compounds broadly active against Rift Valley fever virus and other highly pathogenic RNA viruses.

Mudhasani R, Kota KP, Retterer C, Tran JP, Whitehouse CA, Bavari S.

PLoS Negl Trop Dis. 2014 Aug 21;8(8):e3095. doi: 10.1371/journal.pntd.0003095. eCollection 2014 Aug.


High-content image-based screening of a signal transduction pathway inhibitor small-molecule library against highly pathogenic RNA viruses.

Mudhasani R, Kota KP, Retterer C, Tran JP, Tritsch SR, Zamani R, Whitehouse CA, Bavari S.

J Biomol Screen. 2015 Jan;20(1):141-52. doi: 10.1177/1087057114556253. Epub 2014 Oct 23.


RNA polymerase I-mediated expression of viral RNA for the rescue of infectious virulent and avirulent Rift Valley fever viruses.

Billecocq A, Gauliard N, Le May N, Elliott RM, Flick R, Bouloy M.

Virology. 2008 Sep 1;378(2):377-84. doi: 10.1016/j.virol.2008.05.033. Epub 2008 Jul 9.


Quantitative real-time PCR detection of Rift Valley fever virus and its application to evaluation of antiviral compounds.

Garcia S, Crance JM, Billecocq A, Peinnequin A, Jouan A, Bouloy M, Garin D.

J Clin Microbiol. 2001 Dec;39(12):4456-61.


Wicking assay for the rapid detection of Rift Valley fever viral antigens in mosquitoes (Diptera: Culicidae).

Turell M, Davé K, Mayda M, Parker Z, Coleman R, Davé S, Strickman D.

J Med Entomol. 2011 May;48(3):628-33.


Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment.

Scharton D, Bailey KW, Vest Z, Westover JB, Kumaki Y, Van Wettere A, Furuta Y, Gowen BB.

Antiviral Res. 2014 Apr;104:84-92. doi: 10.1016/j.antiviral.2014.01.016. Epub 2014 Jan 31.


A Haploid Genetic Screen Identifies Heparan Sulfate Proteoglycans Supporting Rift Valley Fever Virus Infection.

Riblett AM, Blomen VA, Jae LT, Altamura LA, Doms RW, Brummelkamp TR, Wojcechowskyj JA.

J Virol. 2015 Nov 18;90(3):1414-23. doi: 10.1128/JVI.02055-15.


Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses.

Han Z, Lu J, Liu Y, Davis B, Lee MS, Olson MA, Ruthel G, Freedman BD, Schnell MJ, Wrobel JE, Reitz AB, Harty RN.

J Virol. 2014 Jul;88(13):7294-306. doi: 10.1128/JVI.00591-14. Epub 2014 Apr 16.


Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus.

Näslund J, Lagerqvist N, Habjan M, Lundkvist A, Evander M, Ahlm C, Weber F, Bucht G.

Virology. 2009 Mar 15;385(2):409-15. doi: 10.1016/j.virol.2008.12.012. Epub 2009 Jan 20.


Development and characterization of a Rift Valley fever virus cell-cell fusion assay using alphavirus replicon vectors.

Filone CM, Heise M, Doms RW, Bertolotti-Ciarlet A.

Virology. 2006 Dec 5-20;356(1-2):155-64. Epub 2006 Aug 30.


Efficient production of Rift Valley fever virus-like particles: The antiviral protein MxA can inhibit primary transcription of bunyaviruses.

Habjan M, Penski N, Wagner V, Spiegel M, Overby AK, Kochs G, Huiskonen JT, Weber F.

Virology. 2009 Mar 15;385(2):400-8. doi: 10.1016/j.virol.2008.12.011. Epub 2009 Jan 19.


Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation.

Ikegami T, Narayanan K, Won S, Kamitani W, Peters CJ, Makino S.

PLoS Pathog. 2009 Feb;5(2):e1000287. doi: 10.1371/journal.ppat.1000287. Epub 2009 Feb 6.


Creation of Rift Valley fever viruses with four-segmented genomes reveals flexibility in bunyavirus genome packaging.

Wichgers Schreur PJ, Oreshkova N, Moormann RJ, Kortekaas J.

J Virol. 2014 Sep;88(18):10883-93. doi: 10.1128/JVI.00961-14. Epub 2014 Jul 9.


Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice.

Papin JF, Verardi PH, Jones LA, Monge-Navarro F, Brault AC, Holbrook MR, Worthy MN, Freiberg AN, Yilma TD.

Proc Natl Acad Sci U S A. 2011 Sep 6;108(36):14926-31. doi: 10.1073/pnas.1112149108. Epub 2011 Aug 23.


Rift Valley fever virus clearance and protection from neurologic disease are dependent on CD4+ T cell and virus-specific antibody responses.

Dodd KA, McElroy AK, Jones ME, Nichol ST, Spiropoulou CF.

J Virol. 2013 Jun;87(11):6161-71. doi: 10.1128/JVI.00337-13. Epub 2013 Mar 27.


Identification of Rift Valley fever virus nucleocapsid protein-RNA binding inhibitors using a high-throughput screening assay.

Ellenbecker M, Lanchy JM, Lodmell JS.

J Biomol Screen. 2012 Sep;17(8):1062-70. doi: 10.1177/1087057112448100. Epub 2012 May 29.


The use of NanoTrap particles as a sample enrichment method to enhance the detection of Rift Valley Fever Virus.

Shafagati N, Narayanan A, Baer A, Fite K, Pinkham C, Bailey C, Kashanchi F, Lepene B, Kehn-Hall K.

PLoS Negl Trop Dis. 2013 Jul 4;7(7):e2296. doi: 10.1371/journal.pntd.0002296. Print 2013.


Rift valley Fever virus encephalitis is associated with an ineffective systemic immune response and activated T cell infiltration into the CNS in an immunocompetent mouse model.

Dodd KA, McElroy AK, Jones TL, Zaki SR, Nichol ST, Spiropoulou CF.

PLoS Negl Trop Dis. 2014 Jun 12;8(6):e2874. doi: 10.1371/journal.pntd.0002874. eCollection 2014 Jun.


Large-scale chromatin immunoprecipitation with promoter sequence microarray analysis of the interaction of the NSs protein of Rift Valley fever virus with regulatory DNA regions of the host genome.

Benferhat R, Josse T, Albaud B, Gentien D, Mansuroglu Z, Marcato V, Souès S, Le Bonniec B, Bouloy M, Bonnefoy E.

J Virol. 2012 Oct;86(20):11333-44. Epub 2012 Aug 15.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk